Lindsay Dixon BSc. Pharm RPh explains how the use of a Nasal Vaccine for COVID-19 from Yale University induces mucosal immune response and long-term protection with induction of cross-reactive immunity against sarbecoviruses.
#NasalVaccine #PrimeandSpike #Yale
References:
Unadjuvanted intranasal spike vaccine booster elicits robust protective mucosal immunity against sarbecoviruses: https://www.biorxiv.org/content/10.1101/2022.01.24.477597v1
Mucosal vaccines — fortifying the frontiers: https://www.nature.com/articles/s41577-021-00583-2
Immune response: https://medlineplus.gov/ency/article/000821.htm
Exploiting Mucosal Immunity for Antiviral Vaccines: https://www.annualreviews.org/doi/10.1146/annurev-immunol-032414-112315?url_ver=Z39.88-2003
Unadjuvanted intranasal spike vaccine booster elicits robust protective mucosal immunity against sarbecoviruses: https://www.biorxiv.org/content/10.1101/2022.01.24.477597v1
Nasal Spray Booster Keeps COVID-19 at Bay: https://www.hhmi.org/news/nasal-spray-booster-keeps-covid-19-bay
Exploiting Mucosal Immunity for Antiviral Vaccines: https://www.annualreviews.org/doi/10.1146/annurev-immunol-032414-112315?url_ver=Z39.88-2003
SARS-CoV-2 infection and persistence throughout the human body and brain: https://assets.researchsquare.com/files/rs-1139035/v1_covered.pdf?c=1640020576
